Nuvalent Announces Pricing of Public Offering of Common Stock

Core Viewpoint - Nuvalent, Inc. has announced a public offering of Class A common stock priced at $101.00 per share, aiming to raise approximately $500 million before expenses [1][2]. Group 1: Offering Details - The company is selling 4,950,496 shares in the offering, with the expected closing date on November 20, 2025, pending customary closing conditions [1]. - Selling stockholders have granted underwriters a 30-day option to purchase an additional 742,574 shares at the public offering price [2]. - J.P. Morgan, Jefferies, TD Cowen, and Cantor are acting as joint book-running managers for the offering [3]. Group 2: Regulatory Information - The shares are being offered under an automatically effective shelf registration statement filed with the SEC on March 16, 2023 [4]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [4]. Group 3: Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, particularly for kinase targets [6]. - The company aims to create innovative small molecules that can overcome resistance and minimize adverse events, with a pipeline targeting ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer [6].